Denali therapeutics announces achievement of ripk1 milestone for phase 2 clinical trial initiation in als by sanofi

South san francisco, calif., may 02, 2022 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases, today announced that its partner sanofi has commenced dosing in a phase 2 study, named himalaya, of sar443820 (dnl788) in individuals with amyotrophic lateral sclerosis (als). sar443820 is a central nervous system (cns)-penetrant small molecule inhibitor of ripk1.
DNLI Ratings Summary
DNLI Quant Ranking